{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-077636","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.797605+00:00","generated_at":"2026-06-01T01:21:53.952115+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint announces Phase 3 plans for DURAVYU in wet AMD; positive Phase 2 data","bullets":["Phase 3 LUGANO and LUCIA trials to enroll ~400 patients each; 2.7mg DURAVYU vs aflibercept; one-year endpoint.","Phase 2 DAVIO 2 data: favorable safety, BCVA nearly identical to aflibercept at 12 months post single injection.","After single DURAVYU dose, ~50% of eyes were supplement-free at 12 months vs 22% for aflibercept control.","Phase 2 VERONA trial in DME fully enrolled with 27 patients; no drug-related SAEs reported.","First patient dosing in Phase 3 LUGANO expected 2H 2024; FDA alignment on non-inferiority design with redosing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-077636","json":"https://secwatch.observer/filing/0000950170-24-077636.json","markdown":"https://secwatch.observer/filing/0000950170-24-077636.md","text":"https://secwatch.observer/filing/0000950170-24-077636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024077636/0000950170-24-077636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024077636/eypt-20240626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:21:53.952115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}